Print

Prevalence of bisphosphonate-related osteonecrosis in patients with cancer could be as high as 13.3 percent Critical Summary Prepared by: Romesh Nalliah BDS 

A Critical Summary of:

A systematic review of bisphosphonate osteonecrosis (BON) in cancer

Migliorati, C. A., Woo, S. B., Hewson, I., Barasch, A., Elting, L. S., Spijkervet, F. K., Brennan, M. T.. Supportive Care in Cancer. 2010;18(8):1099-106

Published Date: 2/1/2012

This summary is published in the Journal of the American Dental Association and can be accessed at :-
http://jada.ada.org/content/143/2/170.full

OVERVIEW

  • Systematic Review Conclusion:

    The overall mean weighted prevalence of bisphosphonate-related osteonecrosis (BON) in the evaluated studies was 6.1 percent, and the overall weighted prevalence of BON in studies with documented follow-up was 13.3 percent.

  • Critical Summary Assessment:

    There is inconsistency in prevalence study results and a lack of studies in which investigators have evaluated quality-of-life issues related to or the economic effects of BON in patients with cancer.

  • Evidence Quality Rating:

    Limited

Rate This Critical Summary






Information in the above "Rate the Critical Summary" box is used by the administrators of this Website to gauge the usefulness of Critical Summaries and make improvements to the program. If you have comments specific to this critical summary and would like to contact the editors, please  Send a Letter to the Editor

x

Letter to the Editor